| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 10/07/2004 | US20040198748 Antihistamines; bronchodilators; antiinflammatory agents; inflammatory bowel disorders |
| 10/07/2004 | US20040198747 Sodium channel blockers |
| 10/07/2004 | US20040198746 Sodium channel blockers |
| 10/07/2004 | US20040198745 Sodium channel blockers |
| 10/07/2004 | US20040198744 Methods of using phenolic guanidine sodium channel blockers |
| 10/07/2004 | US20040198743 Administering synergistic mixture |
| 10/07/2004 | US20040198741 Compounds, compositions and methods for treating or preventing viral infections and associated diseases |
| 10/07/2004 | US20040198740 Therapies relating to combinations of aldose reductase inhibitors and cyclooxygenase-2 |
| 10/07/2004 | US20040198739 Prevention reproduction of virus |
| 10/07/2004 | US20040198738 Preventives or remedies for diseaes caused by enos expression |
| 10/07/2004 | US20040198737 Azaindoles |
| 10/07/2004 | US20040198735 Sulfonyl heteroaryl triazoles as anti-inflammatory/analgesic agents |
| 10/07/2004 | US20040198733 Obesity; antidiabetic agents; cardiovascular disorders; antilipemic agentsl circadian rhythm disorders; hypotensive agents; antidepressants; anxiolytic agents |
| 10/07/2004 | US20040198732 Aminoalkyl-substituted aromatic bicyclic compounds, methods for their preparation and their use as pharmaceuticals |
| 10/07/2004 | US20040198731 Antidiabetic agents; cardiovascular disorders; anticholesterol agents; antidepressants; schizophrenia; antilipemic agents; circidian rhythm disorders |
| 10/07/2004 | US20040198730 Pyridylfurans and pyrroles as raf kinase inhibitors |
| 10/07/2004 | US20040198727 Compounds that abrogate DNA-damage-induced cell cycle G2 checkpoint and/or augment the anti-cancer activity of DNA damaging treatments |
| 10/07/2004 | US20040198726 Tri-and tetraaza-acenaphthylen derivatives as crf receptor antagonists |
| 10/07/2004 | US20040198724 Contacting a cell with a quinazolinones containing sulfur or its oxides in an amount sufficient to open the potassium channels for the treatment of central or peripheral nervous system disorders |
| 10/07/2004 | US20040198723 administration of a therapeutically effective amount of devazepide to a patient undergoing opioid analgesic therapy for minimising or mitigating the side effects of the opioid |
| 10/07/2004 | US20040198722 Pyrrolobenzodiazepines on solid supports; |
| 10/07/2004 | US20040198720 3-(Arylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors |
| 10/07/2004 | US20040198719 Antagonist of MCP-1 function, and compositions and methods of use thereof |
| 10/07/2004 | US20040198718 Naphthyridine derivatives, processes for their preparation, their use and pharmaceutical compositions comprising them |
| 10/07/2004 | US20040198717 4-(trifluoromethyl)-7,8,9,10-tetrahydrochromeno[7,6-b]azepin-2(6H)-one and derivatives;4-(trifluoromethyl)-1,6,7,8,9,10-hexahydro-2H-azepino[3,2-g]quinolin-2-one and derivatives; useful in the treating conditions caused by androgen deficiency such as bone disorders |
| 10/07/2004 | US20040198715 prolonged serum half-life to permit treatment regimens of about once every 5-7 days or longer, while retaining antibacterial properties in vivo |
| 10/07/2004 | US20040198713 At least one sulfur-containing s-triazine; at least one pyrithione metal salt; and at least one additional microbicide selected from 2-alkyl-4-isothiazolin-3-ones and halopropynyl carbamates |
| 10/07/2004 | US20040198711 steroids formulated in topical dosage form, as creams, gels or suppositories used for therapy or prohylaxis of symptoms associated with menopause |
| 10/07/2004 | US20040198710 suppressing follicle maturation and ovulation and replacing the endogenous ovarian secretion of 17 beta-estradiol; 1,3,5 (10)-estratrien-3, 15 alpha ,16 alpha ,17 beta -tetrol for example; does not employ co-administration of a luteinizing hormone releasing hormone; less side effects |
| 10/07/2004 | US20040198709 Compositions and methods for enhancing corticosteroid delivery |
| 10/07/2004 | US20040198708 For orienting and positioning a capsule containing a dry powder pharmaceutical formulation ( a short-acting bronchodilator and a corticosteroid) to be administered via inhalation to a patient with a pulmonary disease |
| 10/07/2004 | US20040198707 kit containing a plurality of daily hormone units for use in a contraceptive method contains three consecutive phases: an estrogenic, a progestogenic and a hormone-free phase |
| 10/07/2004 | US20040198706 active agent (not testosterone alone ) and a delivery vehicle containing an alkanol, a polyalcohol, and a permeation enhancer to provide permeation enhancement of the active mammalian dermal or mucosal surface; free of long chain fatty acid, fatty ester and fatty alcohol to avoid odor and irritation |
| 10/07/2004 | US20040198704 Compositions and method for treating microbial and parasitic infections in cattle and other animals |
| 10/07/2004 | US20040198701 EP4 receptor agonist, compositions and methods thereof |
| 10/07/2004 | US20040198699 Composition and method for the treatment of dysglucaemia |
| 10/07/2004 | US20040198698 Nitrate ester-cyclodextrin complexes |
| 10/07/2004 | US20040198697 Compositions for the regulation of cytokine activity |
| 10/07/2004 | US20040198696 Agent and food for inhibiting IgE antibody |
| 10/07/2004 | US20040198695 One or more cartilage- and synovial fluid-enhancing active ingredients with bone-enhancing calcium and phosphorus additives |
| 10/07/2004 | US20040198694 Formulation to treat or prevent parasitic infection |
| 10/07/2004 | US20040198692 C-pyrazole A2A receptor agonists |
| 10/07/2004 | US20040198689 Ribozyme sequences related to hiv resistance |
| 10/07/2004 | US20040198688 for treatment of atopic conditions (dermatitis, allergies); point mutations |
| 10/07/2004 | US20040198685 For prophylaxis and therapy of cancer, an autoimmune disorder, airway inflammation, inflammatory disorders, skin disorders, allergy, asthma or a disease caused by a pathogen |
| 10/07/2004 | US20040198682 RNA interference mediated inhibition of placental growth factor gene expression using short interfering nucleic acid (siNA) |
| 10/07/2004 | US20040198677 macrolide and steroidal or non-steroidal substructures connected by an alkyl linker; esterification or amidation to couple; antiarthritic, antiasthmatic agents, nasal, gastrointestinal, dermatological and opthalmic disorders; veterinary or human therapy |
| 10/07/2004 | US20040198676 topical veterinary formulations, such as spot-on and pour-on formulations, which are used in treating, controlling and preventing of endo and ectoparasite infections in warm-blooded animals or birds, such as horses, cattle, sheep, pigs and pets |
| 10/07/2004 | US20040198675 Administering macrolide antibiotic |
| 10/07/2004 | US20040198674 Compositions for preventing hormone induced adverse effects |
| 10/07/2004 | US20040198673 Composition for epigallocatechin gallate |
| 10/07/2004 | US20040198672 a microbiocide and a bioenhancer; 4-((1,3-benzodioxol-6-yl)-1,3-butadien-1-yl)-N-carbonylpiperidine and 3',5-Dihydroxy flavone 7-O- beta -D-galacturonide-4'-O- beta -D-glucopyranoside; reduced antibiotic resistance |
| 10/07/2004 | US20040198671 Estrogenic component comprising estetrol and estetrol-like substances, which has relatively low estrogenic potency, metabolic stability, long half-life; triene steroids; osteoporosis, arteriosclerosis, cognitive disturbances, Alzheimer's disease, peri- or post-menopausal disorders |
| 10/07/2004 | US20040198669 Novel nitrile glycoside useful as a bioenhancer of drugs and nutrients, process of its isolation from moringa oleifera |
| 10/07/2004 | US20040198668 synergistic admnistration of a weight-loss promoting anticonvulsant and a norepinephrine or dopamine agonist; hypotensive, antidiabetic, anticholesterol agents |
| 10/07/2004 | US20040198667 neutralization of diphenhydramine maleate with sodium hydroxide; reacting melted diphenhydramine free base with tannic acid neat or with minimal water; vacuum drying; milling into free-flowing powder; high purity, extended release antihistamine |
| 10/07/2004 | US20040198664 synergistic mixture of the phenaceticacid or 2-(2-hydroxyethoxy)ethyl ester, a phospholipid lung surfactant mixture, and a recombinant lung surfactant protein with point mutations |
| 10/07/2004 | US20040198659 Therapy and diagnosis of conditions related to telomere length and/or telomerase activity |
| 10/07/2004 | US20040198652 using an antiendotoxin with an activated Protein C; continuous infusion, bolus, or intermittent infusion |
| 10/07/2004 | US20040198651 Secreted proteins |
| 10/07/2004 | US20040198649 a VR4 peptide, a VR4 polypeptide modulator, a VR4 polynucleotide, or an antisense agent as analgesics or antiarthritic agents for bone and cartilage disorders; rheumatoid and osteoarthritis, osteoperosis; biodrugs |
| 10/07/2004 | US20040198644 Integrin inhibitors for the treatment of eye diseases |
| 10/07/2004 | US20040198639 Mixture with non-formaldehyde preservative; microbiocides; chemical resistance; drugs, medical equipment, cosmetics; antiaging, wrinkle resistance; skin disorders |
| 10/07/2004 | US20040198638 Administering docetaxel or paclitaxel derivative conjugated to polyglutamic acid, polyaspartic acid, or polylysine as antitumor or anticarcinogenic agent; radiation; autoimmune disorders, rheumatoid arthritis; coatings of stents for prevention of restenosis |
| 10/07/2004 | US20040198636 Administering 2,2*-dipyridyl, deferiprone, deferoxamine, mimosine, and/or ciclopirox or derivatives thereof to inhibit both deoxyhypusine hydroxylase and prolyl 4-hydroxylase; antiproliferative and antitumor agents |
| 10/07/2004 | US20040198634 Docusate sodium and/or ethylene oxide-propylene oxide copolymer wetting agent and megestrol acetate; storage stability, shelf life; free of polyethylene glycol, propylene glycol, sorbitol or glycerol |
| 10/07/2004 | US20040198633 Fungicide against Candida, Entomocorticum, Stereum, Phellinus, Peniophora, Xilaria, Rosellinia, Multiclavula, Hericium, and/or Tricholoma; flucytosine, miconazole,ketoconazole, fluconazole, amphotericin B extracted from culture of Streptomyces and/or nystatin |
| 10/07/2004 | US20040198164 Manikin and eye device apparatus, methods and articles of manufacture |
| 10/07/2004 | US20040197887 MIxtures of oxidoreductase enzymes, nicotinamido adenine dinucleotide coenzyme and vasodilators, complexed with phosphatides in solution, used for prophylaxis of hair loss |
| 10/07/2004 | US20040197827 Contacting with Ewing sarcoma protein and nuclear receptor; determining binding and changes in ligand-induced activity; use in diagnosis and treatment |
| 10/07/2004 | US20040197798 Using alteration in phosphorylation to detect, diagnose, prevent and prognose cell proliferative disorders |
| 10/07/2004 | US20040197786 Method of examining steroid resnponsiveness |
| 10/07/2004 | US20040197765 System for stabilizing samples |
| 10/07/2004 | US20040197469 Apparatus and method for preparing microparticles |
| 10/07/2004 | US20040197431 Use of anabolic agents, anti-catabolic agents, antioxidant agents, and analgesics for protection, treatment and repair of connective tissues in humans and animals |
| 10/07/2004 | US20040197430 detoxification; Alpha Lipoic Acid; Calcium d-glucarate; plant extracts; vitamins |
| 10/07/2004 | US20040197427 Herbal composition for improving anticancer activity, immune response and hematopoiesis of the body, and protecting the body from oxidative damage, and the method of preparing the same |
| 10/07/2004 | US20040197426 Use of phyllanthus constituents for treating or preventing infections caused by hepatit |
| 10/07/2004 | US20040197425 by calcium-containing dietary product; metabolic consumption of adipose tissue, metabolic change, regulation of body weight, weight loss, reduced weight gain, fat loss, and reduced fat gain |
| 10/07/2004 | US20040197424 Dietary plans based on calcium |
| 10/07/2004 | US20040197423 Method of reducing risk of a weight-related health disease |
| 10/07/2004 | US20040197422 an antibacterial agent (hepenicillin, cephalosporin, cloxacillin and cloxacillin benzath) in an oil-base (peanut oil) and a seal formulation comprising a gel base (aluminium stearate) and a non-toxic heavy metal salt (bismuth sub-nitrate); cattle |
| 10/07/2004 | US20040197421 Compositions and methods for the treatment of primary and metastatic neoplastic diseases using arsenic compounds |
| 10/07/2004 | US20040197420 Compositions and methods for the treatment of primary and metastatic neoplastic diseases using arsenic compounds |
| 10/07/2004 | US20040197417 Having a reduced level of residual solvent(s); controlled-release microparticles having improved shelf-life |
| 10/07/2004 | US20040197416 contains dehydroepiandrosterone (DHEA) or its derivatives, aqueous medium, a polymer shell and a lipid core containing an oily solvent |
| 10/07/2004 | US20040197415 Stable pharmaceutical compositions of dalbavancin and methods of administration |
| 10/07/2004 | US20040197412 combining active ingredients with a supercritical carbon dioxide , and separating the active ingredients (antibiotics) from the supercritical fluid to yield a dry powder precipitate |
| 10/07/2004 | US20040197411 Acceptably non-hygroscopic formulation intermediate comprising a hygroscopic drug |
| 10/07/2004 | US20040197410 uniformly contains pullulan and a non-reducing saccharide(s) composed of glucose units, has an improved rate of water dissolution, and retains a satisfactory resistance to humidity; culturing a microorganism capable of producing pullulan followed by purification |
| 10/07/2004 | US20040197409 a prosthetic device (sleeve) placed on the outside surface of the vessel or graft which then elutes antiproliferative drugs or agents from a drug-eluting matrix material; flexible, cylindrical, bioabsorbing, agent-eluting matrix with a vascular-sized lumen |
| 10/07/2004 | US20040197408 Amino acids in micelle preparation |
| 10/07/2004 | US20040197406 Stool softener and enteric coated bisacodyl; tablets, capsule; laxative; administering the drug |
| 10/07/2004 | US20040197405 Multiparticulate modified release composition |
| 10/07/2004 | US20040197404 Extended release oral dosage form |
| 10/07/2004 | US20040197403 dry admixing paroxetine and dry excipients (sodium starch glycollate, dicalcium phosphate and magnesium stearate), compressing it into a slug material or roller it into a strand material, and milling the prepared material into a free flowing mixture; compressing the mixture into tablets; antidepressant |
| 10/07/2004 | US20040197402 Oxcarbazepine dosage forms |
| 10/07/2004 | US20040197401 Adding a sulfated polysaccharide component, such as a carrageenan compound; orally administrable pharmaceutical composition |
| 10/07/2004 | US20040197400 Immediate release medicinal compositions for oral use |
| 10/07/2004 | US20040197399 N-fatty acid-amino acid conjugates and therapeutic uses |